Katherine Chang, MD
Hematology & Oncology · Seattle, WANPI 1427289982
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $172 of the $191 with a category attached, or 89.9%. Sanofi Pasteur Inc. accounts for 65.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $48 and has fallen 64.3% since, to $17 in 2024. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 10 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$126
- Karyopharm Therapeutics Inc.$47
- E.r. Squibb & Sons, L.L.C.$19
Across 10 payments — averaging $7669.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$39K
- Pfizer$37K
What the payments were for
- Food & beverage$17290%
- Education$1910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 6 | $126 |
| Karyopharm Therapeutics Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
How this compares
$191 in reported general payments places this provider in the 25th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 23 | $325,114 |
| JakafiRuxolitinib Phosphate | 16 | $238,817 |
| EliquisApixaban | 37 | $26,974 |
| Anastrozole | 33 | $644 |
| Oxycodone Hcl | 17 | $531 |
| Hydroxyurea | 18 | $464 |
| Potassium Chloride | 25 | $264 |
| LoperamideLoperamide Hcl | 22 | $260 |
| Prochlorperazine Maleate | 17 | $213 |
| Ondansetron Hcl | 25 | $196 |
| Acyclovir | 16 | $159 |
| Famotidine | 11 | $138 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $125 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.